About Us｜J-Pharma Co., Ltd.

Corporate Philosophy

Our corporate philosophy is to "By pursuing new possibilities for SLC transporters and developing innovative new drugs that address unmet medical needs, we will contribute to supporting people around the world to maintain good health and hope." Based on this philosophy, we will work to create innovative pharmaceuticals to achieve sustainable corporate growth and increase social value.
In addition, we have established the following three codes of conduct to realize our corporate philosophy

Passion to challenge as a global venture company
The pursuit of science
Strict adherence to compliance

Management Policy

Goals for 2030

We have established the following “Goals for 2030” as part of our long-term management strategy and are steadily implementing phased initiatives toward their achievement.

Obtain global approval for LAT1 inhibitor (Nanvuranlat, First-in-Class) as a monotherapy for BTC
・Aiming for a blockbuster product from Japan (annual sales of USD 1B)
Pursue potential of immune mechanisms, expanding indications into other cancers, autoimmune diseases, and rare diseases
Advance next-generation LAT1 inhibitors (Best-in-Class) into clinical trials
Expand pipeline through the creation of novel transporter inhibitors
Build a sustainable drug discovery and business platform by integrating diverse drug discovery technologies

Company Information

Company name	J-Pharma Co., Ltd
Head office	8th Floor, VORT Hamamatsucho II 1-10-11 Hamamatsucho, Minato-ku, Tokyo 105-0013 TEL: General inquiries (main number) +81-3-6432-4270 Inquiries from investors (Contact IR) +81-3-6450-1146 FAX: +81-3-6432-4271
Founded	December 26, 2005
Representative	Masuhiro Yoshitake (President & CEO)
Capital stock	JPY 2,033 million (as of March 31, 2026)
Accounting period	March 31
Business description	Research & Development of pharmaceutical drugs
Number of employees	18 (as of March 31, 2026)

Access Map

" style="border:0;" allowfullscreen="" loading="lazy" referrerpolicy="no-referrer-when-downgrade">

Board of Directors

President and CEO

Masuhiro Yoshitake

40 years of industry experience
Over 30 years in global leadership roles at major pharma; achieved FDA and EMA approval for 3 drugs
Successfully completed domestic Phase II study of the company’s lead compound; global Phase III to initiate (FDA agreement obtained)

Director CFO

Yutaka Fujimoto

20 years of industry experience
Global marketing experience at consulting firms and major pharmaceutical company
Founded a startup, increased its valuation 200-fold, and sold it to a fund
Led cumulative fundraising of JPY 9B for the company

Outside Director

Yasuo Miura

Served in various leadership roles at Shimadzu Corporation, including General Manager of the Corporate Strategy Office and President of its European subsidiary
Appointed Director of Shimadzu Corporation in 2013, while also serving as Executive Officer responsible for sales, finance and treasury, risk management, and Chief Financial Officer (CFO) functions
Has served as Executive Advisor to Shimadzu Corporation since April 2023
Appointed Outside Director of the Company in June 2025

Outside Director and Audit & Supervisory Committee Member

Shunsuke Mori (Doctor of Pharmacy, Pharmacist)

Over 30 years of experience in the biotechnology and pharmaceutical industry, including drug discovery research, antibody therapeutics development, and new business creation at the U.S. National Cancer Institute and Takeda Pharmaceutical Company
Led hands-on investments in biotech startups at an investment firm/venture capital fund; as Representative of TM Partners, supports commercialization of academic technologies, venture development, and talent development, and has served as an outside director at multiple companies
Has served as an Outside Director of the Company since 2020 and as an Outside Director (Audit and Supervisory Committee Member) since 2023

Outside Director and Audit & Supervisory Committee Member

Teruhisa Tajima (Certified Public Accountant)

Established Tajima Certified Public Accounting Firm in 2010 and has provided management control and fundraising support primarily to biotechnology startups
Has served as an Outside Director and Auditor for multiple biotechnology and drug discovery companies, with deep expertise in finance, accounting, and intellectual property
Appointed Outside Director (Audit and Supervisory Committee Member) of the Company in 2023

Outside Director and Audit& Supervisory Committee Member

Kosaku Kawaguchi (Lawyer)

Currently provides broad legal support in corporate law, compliance, and related areas at Kitamura, Kato & Sano Law Office
Contributed to governance and risk management as Outside Director/Auditor at listed companies
Joined the Company as Outside Corporate Auditor in 2023 and appointed Outside Director (Audit and Supervisory Committee Member) in October 2023

Corporate Governance

The Company's basic management policy is to ensure management transparency to shareholders and other stakeholders and to continuously increase corporate value by conducting rational and efficient management activities.

The outline of the Company's corporate governance system is as follows.

History

Dec 2005	J Pharma Co., Ltd. was established in Toranomon 1 chome, Minato ku, Tokyo, as a company specializing in drug development targeting membrane transporters
Oct 2006	Awarded the Medical Device Practical Research Support Project funded by the National Institute of Biomedical Innovation for “Development of drug for treating hyperphosphatemia”
Oct 2006	Relocated the head office to Shinjuku 2-chome, Shinjuku-ku, Tokyo
Sep 2007	Awarded Innovation Practical Application Project from New Energy and Industrial Technology Development Organization (NEDO) for “Development of scirrhous stomach cancer therapy”
Oct 2007	Awarded Molecular Imaging Research Program from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) for “Development of novel molecular probes targeting cancer cell-specific membrane proteins” by J-Pharma
Aug 2009	Awarded Innovation Promotion Project from NEDO for “R&D project and clinical phase I study of a novel phosphoric acid adsorbent JPH101”
Aug 2010	Awarded Technology Development for Promoting the Transfer of Basic Research to Clinical Research from NEDO for “Research and Development of a New Anticancer Therapy Targeting Essential Amino Acid Transporter (LAT1) Expressed in Cancer Cells”
Apr 2013	Awarded Venture Practical Application Grant Project from NEDO for “Clinical development of an innovative anticancer drug by inhibiting amino acid transporter”
May 2013	Relocated the head office to Tsurumi-ku, Yokohama, Kanagawa Prefecture
Jul 2013	Awarded a Special Zone Leading Project Grant from Yokohama City for “Development of an in vitro diagnostic kit for triple-negative malignant breast tumor” by J-Pharma
May 2014	Awarded Venture Practical Application Grant Project from NEDO for “Establishing POC of a novel anti-cancer drug JPH203 by clinical trials” by J-Pharma
Jul 2014	Awarded a Special Zone Leading Project Grant from Yokohama City for “Commercial application of in vitro diagnostics for triple-negative breast cancer” by J-Pharma
Jan 2015	Initiated a Phase I clinical trial of the LAT1 inhibitor Nanvuranlat (development code: JPH203) in Japan
Jul 2017	Completed Phase I study of nanvuranlat (Development code: JPH203)
Nov 2018	Started Phase II study of nanvuranlat (Development code: JPH203) in Japan
Apr 2019	Concluded an agreement with Ohara Pharmaceutical Co., Ltd. for licensing and co-development of nanvuranlat
Apr 2022	Obtained Orphan Drug Designation from the U.S. FDA for nanvuranlat (Development code: JPH203) for the treatment of advanced biliary tract cancer
Dec 2022	Completed Phase II study of nanvuranlat (Development code: JPH203) in Japan
Oct 2023	Awarded Fast Forward Commercial Research Grant from the National Multiple Sclerosis Society (NMSS) for the development of the CNS-penetrant LAT1 inhibitor JPH034 for multiple sclerosis
Oct 2023	Established J-Pharma USA for the purpose of talent recruitment to support pharmaceutical development activities in the United States. (liquidated in July 2025)
Jun 2024	JPH034 was selected for the Drug Discovery Venture Ecosystem Enhancement Program of the Japan Agency for Medical Research and Development (AMED)
Sep 2024	Obtained U.S. FDA clearance of the IND application to initiate clinical trials in cancer patients
May 2025	Received positive feedback from the U.S. FDA regarding the CMC (Chemistry, Manufacturing and Controls) of nanvuranlat, confirming that it meets the quality standards required by the FDA at a commercial manufacturing scale
Jun 2025	Relocated the head office to Hamamatsucho, Minato-ku, Tokyo
Dec 2025	Started a global Phase III study of nanvuranrlat (Development code: JPH203) for second-line treatment of biliary tract cancer.
Feb 2026	The IND safety review for JPH034 has been completed in preparation for the initiation of a Phase I clinical trial in the U.S.